PROVECTUS BIOPHARMACEUTICALS, INC. — fact timeline
Source-grounded facts extracted from PROVECTUS BIOPHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PROVECTUS BIOPHARMACEUTICALS, INC.: Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028 (effective 2026-01-30).
“On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.”
Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..
“appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.”
Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..
“appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.”
Material Agreements
PROVECTUS BIOPHARMACEUTICALS, INC. entered into Exclusive License Agreement with University of Miami (effective 2024-03-21).
“On March 21, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (the “University”) for the license and development of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology.”
Dominic Rodrigues was appointed as Chief Operations Consultant at PROVECTUS BIOPHARMACEUTICALS, INC..
“the Board retained Dominic Rodrigues as the Company’s chief operations consultant.”
Bruce Horowitz resigned as Director at PROVECTUS BIOPHARMACEUTICALS, INC..
“On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.”
Bruce Horowitz resigned as Chief Operating Officer at PROVECTUS BIOPHARMACEUTICALS, INC..
“On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.